logo

For the Inventor, By the Inventor

Noblesville, IN, United States of America

Guoxin Zhu

This inventor holds 23 USPTO granted patents and 1 published patent application and 5 EPO patents, primarily in Pharmaceutical Compounds. Top assignee: Eli Lilly and Company. Active years: 2005-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Guoxin Zhu. Retrieved from https://idiyas.com/inventor/guoxin-zhu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 23 

% Patents Active = 17.4

 

Average Co-Inventor Count = 4.3

ph-index = 5

Forward Citations = 81(Granted Patents)


Location History:

  • Indianapolis, IN (US) (2009)
  • Noblesville, IN (US) (2005 - 2011)
  • Shanghai, CN (2010 - 2011)
  • Carmel, IN (US) (2013 - 2014)

Company Filing History:

goldMedal23 out of 4,522 
 
Eli Lilly and Company
 patents

Years Active: 2005-2014

Loading Chart...
Loading Chart...
Areas of Expertise:
Glucagon Receptor Antagonists
PPAR Modulators
Thiophene Derivatives
Sulfonamide Derivatives
Fused Heterocyclic Derivatives
Bicyclic Derivatives
GSK-3 Inhibitors
Oxazolyl-Aryloxyacetic Acid
Proliferative Diseases
Therapeutic Uses
Preparation Methods
Pharmaceutical Innovation
23 patents (USPTO):Explore Patents
1. 8691856 - Glucagon receptor antagonists, preparation and therapeutic uses (2014-04-08),
2. 8609892 - Glucagon receptor antagonists, preparation and therapeutic uses (2013-12-17),
3. 8084489 - Glucagon receptor antagonists, preparation and therapeutic uses (2011-12-27),
4. 8076374 - Glucagon receptor antagonists, preparation and therapeutic uses (2011-12-13),
5. 7989457 - Glucagon receptor antagonists, preparation and therapeutic uses (2011-08-02),
6. 7863329 - Glucagon receptor antagonists, preparation and therapeutic uses (2011-01-04),
7. 7816557 - Glucagon receptor antagonists, preparation and therapeutic uses (2010-10-19),
8. 7807702 - Substituted thiophene carboxylic amide glucagon receptor antagonists, preparation and therapeutic uses (2010-10-05),
9. 7696248 - Glucagon receptor antagonists, preparation and therapeutic uses (2010-04-13),
10. 7655641 - Sulfonamide derivatives as PPAR modulators (2010-02-02),
11. 7598266 - Fused heterocyclic derivatives as PPAR modulators (2009-10-06),
12. 7544707 - Bicyclic derivatives as PPAR modulators (2009-06-09),
13. 7528160 - Fused heterocyclic derivatives as PPAR modulators (2009-05-05),
14. 7504433 - Thiophene derivative PPAR modulators (2009-03-17),
15. 7405305 - Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors (2008-07-29),

Title: Guoxin Zhu: Innovating Diabetes Treatment with Glucagon Receptor Antagonists

Introduction:

Guoxin Zhu, a prolific inventor based in Noblesville, IN, has made significant strides in the field of pharmaceuticals with his groundbreaking inventions. Holding an impressive portfolio of 23 patents, Zhu is recognized for his contributions to diabetes treatment innovation.

Latest Patents:

Among his latest achievements are patents for Glucagon receptor antagonists, focusing on the development of novel compounds with glucagon receptor antagonist or inverse agonist activity. These compounds, in Formula (I), offer promising therapeutic uses in treating diabetic and other glucagon-related metabolic disorders.

Career Highlights:

Guoxin Zhu is affiliated with Eli Lilly and Company, a renowned pharmaceutical giant known for its cutting-edge research and development in life-saving medications. His association with such a prestigious company underscores his expertise and dedication to advancing healthcare through innovation.

Collaborations:

Zhu has collaborated with esteemed colleagues such as Scott Eugene Conner and Nathan Bryan Mantlo, further enhancing his impact in the pharmaceutical industry. The synergy created by these collaborations has led to the development of groundbreaking solutions for complex medical conditions.

Conclusion:

In conclusion, Guoxin Zhu's pioneering work in developing Glucagon receptor antagonists showcases his commitment to revolutionizing diabetes treatment. His relentless pursuit of innovation, coupled with his collaborative efforts, establishes him as a key figure in the realm of pharmaceutical inventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…